NOX4 and Related Biomarkers in ADPKD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-40
SponsorMayo Clinic
About this trial
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
Eligibility criteria
Qualifiers
ADPKD (based on Ravine et al. criteria)
Class 1 A-E according to imaging classification
Male and female subjects 15 - 40 years of age
Estimated GFR> 70 mL/min/1.73 m2 (CKD-EPI)
Disqualifiers
Class 2 according to imaging classification
Concomitant systemic disease affecting the kidney
Diabetes mellitus
Predicted urine protein excretion in >1 g/24 hrs
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 1 trial groupSponsors and collaborators
Mayo Clinic
Lead sponsor
Polycystic Kidney Disease Foundation
Collaborator
Source ClinicalTrials.gov